A Phase I, Open-label, Dose Finding, Safety, Tolerability and Exploratory Trial of THEO-260 Administered Via an Intraperitoneal Route in Patients With High Grade Serous or Endometrioid Ovarian Cancer
Latest Information Update: 09 Feb 2026
At a glance
- Drugs THEO 260 (Primary) ; THEO 260 (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer
- Focus Adverse reactions
- Acronyms OCTOPOD-IP
- Sponsors Theolytics
Most Recent Events
- 04 Feb 2026 Planned initiation date changed from 1 Oct 2025 to 26 Feb 2026.
- 13 Oct 2025 Status changed from not yet recruiting to recruiting. Trial has been initiated in collaboration with The University of Texas MD Anderson Cancer Center.
- 08 Oct 2025 Status changed from planning to not yet recruiting.